J&J (JNJ) Secures Full FDA Nod for Rybrevant in Lung Cancer

Johnson & Johnson (JNJ) announced that the FDA granted full approval to its EFGR/MET inhibitor Rybrevant (amivantamab) in non-small cell lung cancer (NSCLC) indication.Following the FDA decision, Rybrevant, in combination with chemotherapy (carboplatin-pemetrexed), is approved for the first-line treatment of patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations. The drug was initially granted accelerated approval for a similar indication in May 2021.Alongside the FDA appro ...